StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)

Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –

Teva Pharmaceutical Industries Free Cash Flow (Teva Non-GAAP Definition) by Quarter

Free Cash Flow (Teva Non-GAAP Definition) ($M)

Teva Pharmaceutical Industries Free Cash Flow (Teva Non-GAAP Definition): $495M in Q3 2026, down 3.9% from a year earlier.

Latest, Q3 2026
495
Period ended Sep 30, 2026
Change on a year earlier
-3.9%
515 in Q3 2025
History
35 quarters
Since Q1 2018
Sources
31
Documents cited below

Where the Q3 2026 figure comes from

“|| Free cash flow | $ | 495 | $ | 515”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Operating cash flow plus beneficial interest collected in exchange for securitized trade receivables and proceeds from divestitures/asset sales, less cash capital investments.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFree Cash Flow (Teva Non-GAAP Definition) ($M)Year on yearSource
Q3 2026Sep 30, 2026495-3.9%Form 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026622+30.7%Form 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 2026188+75.7%Form 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 20251,298+64.3%Form 8-K Earnings Release (0001171843-26-000462) ↗
Q3 2025Sep 30, 2025515-44.1%Form 8-K Earnings Release (0001171843-25-007000) ↗
Q2 2025Jun 30, 2025476+46.9%Form 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 2025107+234.4%Form 8-K Earnings Release (0001171843-25-002849) ↗
Q4 2024Dec 31, 2024790-46.8%Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2024Sep 30, 2024922+302.6%Form 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 2024324-48.7%Form 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 202432-22.0%Form 8-K Earnings Release (0001193125-24-133759) ↗
Q4 2023Dec 31, 20231,486+30.4%Form 8-K Earnings Release (0001157523-24-000137) ↗
Q3 2023Sep 30, 2023229-66.6%Form 8-K Earnings Release (0001157523-23-001677) ↗
Q2 2023Jun 30, 2023632+110.0%Form 8-K Earnings Release (0001157523-23-001212) ↗
Q1 2023Mar 31, 202341-65.0%Form 8-K Earnings Release (0001157523-23-000797) ↗
Q4 2022Dec 31, 20221,140+59.2%Form 8-K Earnings Release (0001157523-23-000205) ↗

Breakdown

What makes up free Cash Flow (Teva Non-GAAP Definition)

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Free Cash Flow (Teva Non-GAAP Definition) ($M), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/fcf-total

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?